Martek plans offsets for formula contracts
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences CEO Steve Dubin says the nutritional oils firm will offset price reductions in extended infant formula supply contracts with Mead Johnson and Danone through formula market growth, new production technologies and expansion of its Amerifit Brands business. Dubin said during an earnings call Sept. 1 that Amerifit will launch five to seven supplement stock-keeping units in 2011 (1"The Tan Sheet" Aug. 16, 2010). Martek reported cost reductions in life'sDHA and life'sARA production, and efficiencies from Amerifit - acquired in January - helped swell its third-quarter gross margin to nearly 50 percent from 44 percent in the year-ago period. Dubin said he expects further margin, revenue and earnings growth in 2011. The Columbia, Md.-based firm recorded net sales of $114 million in the May-July timeframe, a 51.9 percent increase
You may also be interested in...
Martek Plans 2011 Supplement Launches Through Amerifit Subsidiary
Martek Biosciences' dietary supplement pipeline comes into focus as the developer of algae-based omega-3 oils lines up a slate of products to launch in 2011 through its Amerifit Brands business
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.